⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246189 | 1.00 | — | — | |
| SCHEMBL20974864 | 1.00 | — | — | |
| SCHEMBL13162855 | 1.00 | — | — | |
| SCHEMBL21722218 | 1.00 | — | — | |
| SCHEMBL21734081 | 1.00 | — | — | |
| SCHEMBL23060607 | 1.00 | — | — | |
| SCHEMBL8318016 | 1.00 | — | — | |
| SCHEMBL24272944 | 0.79 | — | — | |
| SCHEMBL22789102 | 0.79 | — | — | |
| SCHEMBL24779819 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119431406-A | Tricyclic compounds and medical uses thereof | 正大天晴药业集团股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025026903-A1 | IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-113637005-B | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024061333-A1 | KRAS MUTANT PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 甘李药业股份有限公司 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |